Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Amylyx Pharmaceuticals Logo
Amylyx Pharmaceuticals Growth Score
89
CB Rank
5404
Heat Score
65
Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain.
Founded
obfuscation
PublicPost-IPO Equity Cambridge, Massachusetts, United States101-250 amylyx.com
Biotechnology
Medical
Neuroscience
Pharmaceutical
Overview

Amylyx Pharmaceuticals
Total Funding
obfuscation
Growth Score
89
Heat Score
65

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score89
9 pts
in past quarter
Heat Score 65
0 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Amylyx Pharmaceuticals

CB Rank
5404
Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain.
Founded
obfuscation
PublicPost-IPO Equity Cambridge, Massachusetts, United States101-250 amylyx.com
Biotechnology
Medical
Neuroscience
Pharmaceutical

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Series C
OBF
in
obfuscation

Key People

Details

Legal Name Amylyx Pharmaceuticals Inc
Operating Status Active
Stock Symbol  NASDAQ:AMLX
Company Type For Profit
Founders  Joshua Cohen, Justin Klee
About the Company
Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain. The company features a drug designed to prevent nerve cell death and degeneration.
Predictions & Insights

Growth Insight

See this Growth Insight
Amylyx Pharmaceuticals is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

AMX0035
An oral fixed-dose combination therapy designed to reduce neuronal death and dysfunction in neurodegenerative diseases such as ALS and Wolfram syndrome.
ALBRIOZA™
An oral fixed-dose medication approved in Canada for treating amyotrophic lateral sclerosis (ALS) by reducing neuronal cell death.

Research & Development

Amylyx Pharmaceuticals is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 9
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Amylyx Pharmaceuticals Logo
Post-IPO Equity - Amylyx Pharmaceuticals
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Amylyx Pharmaceuticals Logo
Post-IPO Equity - Amylyx Pharmaceuticals
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Amylyx Pharmaceuticals Logo
Post-IPO Equity - Amylyx Pharmaceuticals
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Amylyx Pharmaceuticals Logo
Post-IPO Equity - Amylyx Pharmaceuticals
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Amylyx Pharmaceuticals Logo
Post-IPO Equity - Amylyx Pharmaceuticals
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 9
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Amylyx Pharmaceuticals Logo
Post-IPO Equity - Amylyx Pharmaceuticals
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Amylyx Pharmaceuticals Logo
Post-IPO Equity - Amylyx Pharmaceuticals
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Amylyx Pharmaceuticals Logo
Post-IPO Equity - Amylyx Pharmaceuticals
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Amylyx Pharmaceuticals Logo
Post-IPO Equity - Amylyx Pharmaceuticals
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Amylyx Pharmaceuticals Logo
Post-IPO Equity - Amylyx Pharmaceuticals
—
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
683 CAPITAL Logo
683 CAPITAL
—
Series C - Amylyx Pharmaceuticals Logo
Series C - Amylyx Pharmaceuticals
—
683 CAPITAL Logo
683 CAPITAL
—
Series C - Amylyx Pharmaceuticals Logo
Series C - Amylyx Pharmaceuticals
—
683 CAPITAL Logo
683 CAPITAL
—
Series C - Amylyx Pharmaceuticals Logo
Series C - Amylyx Pharmaceuticals
—
683 CAPITAL Logo
683 CAPITAL
—
Series C - Amylyx Pharmaceuticals Logo
Series C - Amylyx Pharmaceuticals
—
683 CAPITAL Logo
683 CAPITAL
—
Series C - Amylyx Pharmaceuticals Logo
Series C - Amylyx Pharmaceuticals
—
Market Intelligence
People
View Profiles & Contacts
Headcount 101-250 Employee Profiles 6 Board Members and Advisors 2 Contacts 235

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 4, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 24, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 17, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 16, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

4,603
-26.81%
 in past month

IT Spend

$6.7MThis year, Amylyx Pharmaceuticals is projected to spend $6.7M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Cash Forecasting Logo
Cash Forecasting
100
Active Cyber Defense Logo
Active Cyber Defense
100
Risk Analytics Logo
Risk Analytics
100

Active Website Tech Count

16Amylyx Pharmaceuticals is actively using 16 technologies for its website, according to BuiltWith. These include DNSSEC, Google Cloud, and  CrUX Top 50m.

Total IP

61The intellectual property of Amylyx Pharmaceuticals includes 34 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, Amylyx Pharmaceuticals has registered 27 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Amylyx Pharmaceuticals's headquarters? Amylyx Pharmaceuticals is located in Cambridge, Massachusetts, United States.Who invested in Amylyx Pharmaceuticals? Amylyx Pharmaceuticals has 20 investors including 683 CAPITAL and  aMoon Fund.When was the last funding round for Amylyx Pharmaceuticals? Amylyx Pharmaceuticals closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Amylyx Pharmaceuticals's competitors? Alternatives and possible competitors to Amylyx Pharmaceuticals may include BioAge Labs, PMGC Holdings, and  LEXEO Therapeutics.How much funding has Amylyx Pharmaceuticals raised to date? Amylyx Pharmaceuticals has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(ccb7a32 1)
|